News

Our new brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:

Our newsletter for Q4 2016 features case studies illustrating the creation of sulfated metabolites and, in some cases, co-production of other conjugates.

Hot-off-the-press news describing the scale-up of human metabolites resulting from mixed metabolism of Incyte’s first-in-class IDO1 inhibitor epacadostat (EPA) is the topic of our newsletter for Q3. EPA is currently in Phase III clinical trials in combination with Merck’s pembrolizumab for treatment of metastatic melanoma.

Scientists at Lilly presented a poster at ISSX 2015 summarising results of an evaluation of Hypha’s drug metabolite screening panels. In it they conclude:

Dr Steve Wrigley will be talking at the forthcoming RSC conference “Bioactive Natural Products: Translating Promise into Practice” to be held at St. Catherine’s College, University of Oxford, UK on 11-13 July 2016.

Steve’s talk is entitled, “Diversity and Diversification : Microbial Chemistry for Discovery and Development.”

Hypha will showcase its expertise in DMPK metabolite synthesis at the 3rd New Perspectives in DMPK: the impact of drug design, 8th-9th February 2016 at the Royal Society of Chemistry at Burlington House, London. Hypha are experts in producing up to gram amounts of metabolites that are hard to make synthetically. Hypha’s microbial system mimics mammalian metabolism with a very high success rate and performs difficult reactions including aliphatic hydroxylations and glucuronidations.

The article describes the extraction and subsequent NMR/MS characterisation of novel derivatives of pregaliellalactone from the fungus Galiella rufa. The full article is available via the ScienceDirect website

Our Business Development Manager, Frank Scheffler, will be presenting a poster at the Discovery Chemistry Congress in Berlin, Germany from 17th-18th February 2015.

Please let us know if you are going – Frank would welcome an opportunity to meet you there.

Hypha produces acyl, N- and O-glucuronides of investigational new drugs at >90% purity and in yields typically between 5 and 50mg. Larger (100’s mg to low gram) amounts are sometimes manufactured for more extensive studies. In our December 2014 newsletter, we focusses on custom production of glucuronide metabolites, with a particular focus on acyl glucuronides.

We are showcasing Hypha’s biotransformation capabilities at the ISSX meeting being held in San Francisco from 20th to 23rd October, 2014.

If you are attending ISSX, please drop by and see us at booth 505.

We will be attending the RICT 2014 Interfacing Chemical Biology and Drug Discovery conference, being held in Rouen, France from 2nd-4th July 2014. Come and see our poster entitled ” MICROBIAL HYDROXYLATION OF LEAD COMPOUNDS; A WAY OUT OF THE LIPOPHILIC CUL-DE-SAC”.

We are able to create mammalian metabolites as featured in our May 2014 newsletter, using Cyclosporin A as an example. In addition, we are also able to produce microbial derived metabolites which may have interesting, exploitable properties that have not previously been possible to explore.